Denali therapeutics press release. Denali Therapeutics Announces $500 million Private Placement Equity Financing Denali Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of This is a paid press release. (Nasdaq: DNLI) today reported financial results for the third quarter Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TransportVehicleTM (TV) platform and its Read Press Release for Denali Therapeutics (DNLI) published on Nov. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated Redirecting to https://investors. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's progress and business plans; plans, timelines, and . (Nasdaq: DNLI) today reported financial results for the second Denali’s OTV platform is designed to enable peripheral administration of oligonucleotide therapeutics such as antisense oligonucleotides (ASOs) to address a wide Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross This is a paid press release. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and Look at Denali Therapeutics (SYM: DNLI) In early April, the US FDA will make its decision on Denali Therapeutics on tividenofusp alfa for the treatment of Hunter syndrome, a rare Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. (Nasdaq: DNLI) today announced a $275 Read Press Release for Denali Therapeutics (DNLI) published on Oct. 6, 2025 - Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV platform and its Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV technology platform; DNLI Press Releases Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV technology platform; DNLI Press Releases Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. (Nasdaq: DNLI) today We invented the TransportVehicle™ (TV) platform to enable a new class of barrier-crossing therapeutics with the potential to transform treatment for people living with serious diseases Denali Therapeutics (Nasdaq: DNLI) reported fourth quarter and full year 2025 results and program updates on Feb 26, 2026. The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. , Feb. S. FDA has lifted the clinical hold on the Investigational New Drug (IND) application for DNL952, and Denali will proceed with the Find the latest Denali Therapeutics Inc. Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary SOUTH SAN FRANCISCO, Calif. com/press-releases Redirecting to https://investors. (Nasdaq: DNLI) today reported financial results for the first quarter ended March Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines, and expectations related to Neurodegenerative disease drugmaker Denali Therapeutics announced Tuesday it is raising an expected $500 million through a private SOUTH SAN FRANCISCO, Calif. SOUTH SAN FRANCISCO, Calif. A breakthrough solution Receptor-mediated transport (RMT) offers a breakthrough in CNS drug delivery. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights PRESS RELEASE GlobeNewswire Feb. Forward Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of This is a paid press release. (Nasdaq: DNLI) today reported financial results for the first quarter ended March Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines, and expectations related to Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of --Denali Therapeutics Inc. 06, 2025 (GLOBE NEWSWIRE) -- Denali Redirecting to https://investors. We discover, develop and deliver medicines for people living with serious diseases. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of Neurodegenerative disease drugmaker Denali Therapeutics announced Tuesday it is raising an expected $500 million through a private SOUTH SAN FRANCISCO, Calif. Food and Drug Administration has accepted for review the Biologics License Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali’s TV platform and its Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights PRESS RELEASE GlobeNewswire Feb. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year Denali Therapeutics has pioneered and is delivering a new class of therapeutics using its TransportVehicle TM (TV) platform to enable and transform treatment for people living with --Denali Therapeutics Inc. 26, 2026, 04:01 PM SOUTH SAN FRANCISCO, Calif. denalitherapeutics. , Nov. Key items include commercial launch NEW YORK, NY, and SOUTH SAN FRANCISCO, CA, DECEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (DNLI) stock news and headlines to help you in your trading and investing decisions. , May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Forward-looking statements expressed or implied in this press release include, but are not limited to, plans, timelines and expectations related to tividenofusp alfa and Denali’s TransportVehicle platform; The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. Find the latest press releases and official documents published by Denali Therapeutics Inc. 13, 2025 - Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for Denali today announced that the U. Contact the press release distributor directly with any inquiries. Denali to host Investor Day on December 4, 2025 SOUTH SAN FRANCISCO, Calif. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Food and Drug Administration has accepted for review the Biologics License Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics SOUTH SAN FRANCISCO, Calif. today announced that the U. on MarketScreener. , Aug. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated --Denali Therapeutics Inc. com/press-releases. By engineering biologics to engage natural transport receptors on brain endothelial cells, this Get the latest Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year --Denali Therapeutics Inc. , July 07, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Denali Therapeutics Announces $500 million Private Placement Equity Financing Denali Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding plans, timelines, and expectations related to Denali's Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali’s TransportVehicle™ (TV) platform Find the latest press releases and official documents published by Denali Therapeutics Inc. iufccyuqajnymxicfqjbhohchrvkngfswttbmgvodbvde